Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis
Links shared publicly online about this topic.
- 236total visits
Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis
Aradigm Corporation (OTCBB:ARDM) (the Company) today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the m
View full resource at medicalnewstoday.com
Tags: Bronchiectasis, Diet and Nutrition, Drug, FDA, Antibiotic, Cipro, Ciprobay
Most Recently Shared on June 8, 2011 at 12:36 am By:
Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis: Aradigm Corpora... http://bit.ly/l6RUVx
Also Shared By:
Advertisement
MNT Cystic Fibrosis
@mnt_cysticfibro
Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis http://mnt.to/3WSg #cysticfibrosis
1 year ago...